Regular Review
Timolol after myocardial infarction: an answer or a new set of questions? J R A MITCHELL "How long halt ye between two opinions? . . . Let them therefore give us two bullocks and let them choose one bullock for themselves and cut it in pieces and lay it on wood and put no fire under, and I will dress the other bullock and lay it on wood and put no fire under. And call ye on the name of your gods and I will call on the name of the Lord. And the God that answercth by fire let him be God. And all the people answered and said, it is well spoken." I KINGS XVIII, [21] [22] [23] [24] This early controlled trial illustrates very vividly the advantages and problems of our main tool for investigating the effect of treatment. The end point chosen by Elijah was immediate and clearcut so it could be observed by everyone. It resembled early trials of treatment in previously fatal conditions such as diabetes, pernicious anaemia, and tuberculous meningitis, where the first survivals showed that insulin, liver, and streptomycin respectively worked. This contrasts sharply with trials in chronic diseases, where end points such as death or disability accumulate slowly over many years, leaving ample scope for many variables to influence outcome. Elijah attempted a contemporaneous comparison of like with like, so that the only factor which should have influenced outcome was a difference between the regimens under scrutiny. Purists will immediately see that by allowing the trialists to choose their own bullocks he introduced potential bias. Random allocation would have prevented him from selecting a readily combustible animal for himself whereas his enemies were given a less flammable beast. In our clinical trials we must be sure that the groups used are comparable in all respects other than the variable under scrutiny. An ideal trial thus has a clear and objective end point and is conducted so that the presence or absence of the treatment being tested is the only difference between the groups. Such perfection is unattainable in the real world, especially in chronic conditions with a variable and unpredictable natural history, such as myocardial infarction, stroke, and cancer, where trials are difficult to mount but easy to criticise.
Survival after infarction-When a patient survives his first myocardial infarction he has a 10% chance of dying in the first year. Three hazards still face him.' Firstly, his heart may have been so damaged by ischaemic necrosis that he will develop mechanical pump failure. The only useful strategy here is the primary prevention of the initial infarction or the identification of regimens to limit infarct size. Secondly infarction, drug X will his overall chance of survival or of escaping disability be increased ?" Beta-blockers after infarction: the theory-At least two of the hazards facing an infarct survivor are influenced by the amount of his sympathetic drive, since the incidence of arrhythmias and the work done by the left ventricle are both increased by catecholamines. In animals denervation of the heart by stellate ganglionectomy has been shown to reduce arrhythmias, limit infarct size, and improve survival after coronary ligation,8 9 so the synthesis of beta-blockers offered the possibility that they would modify the natural history of myocardial infarction. The first such drug widely available for clinical use was propranolol, followed over the years by a bewildering range of agents with a variety of properties which need to be described when we try to compare one betablocker with another.'0 Firstly, the ratio between their ability to affect cardiac receptors (P,) and receptors subserving the bronchial wall and other parts of the body (p2) makes agents cardioselective or non-selective. Next, some agents mimic adrenergic activity as well as blocking it-so called partial agonist or intrinsic sympathomimetic activity. Thirdly, some beta-blockers possess a non-specific membranestabilising activity. Fourthly, their lipid solubility varies, and this determines their ability to cross the blood-brain barrier and to produce sedation or anxiolytic effects. Finally, their rate of removal from the body, either on their first circulation (the "first-pass" effect) or subsequently, varies, as does their rate of removal from receptor sites and their metabolic degradation pattern. An adequate description for a betablocker thus needs to state whether it is selective and has intrinsic sympathomimetic activity or membrane-stabilising activity, how lipid soluble it is, and how speedily it is cleared from the body, because these characteristics may confer benefits and problems over and above its beta-blocking activity. Furthermore, in common with many drugs used in cardiovascular disease, such as vasodilators," 12 beta-blockers can affect platelet behaviour and so might modify the third hazard facing an infarct survivor-namely, reinfarction due to thrombotic coronary occlusion. However, the dextroisomers of beta-blockers, which are not themselves beta-antagonists, may, nevertheless, possess platelet-modifying effects so platelet activity and beta-receptor blockade do not necessarily run in parallel. We need to remember these points when we compare the results obtained when beta-blockers are tested in infarct survivors, since the individual members of such a large group may be as diverse in their additional effects as tolbutamide and insulin, both of which lower blood sugar, or sulphinpyrazone and allopurinol, both of which lower urate.
Beta-blockers after infarction: the practice-When propranolol became available an early clinical trial suggested a favourable effect'3 in acute infarction, but later more tightly controlled studies failed to confirm this.'4 16 Trials based on small numbers of patients cannot detect small differences in outcome between the treated and untreated groups, so we must be cautious in claiming that a regimen is of no benefit when the confidence limits of the observed results do not permit this. The need to avoid this type II error is important in assessing the numbers of patients needed in therapeutic trials.17 The next suggestion that beta-blockers could reduce mortality after infarction came from the G6teberg group, who, in a late entry trial, found that seven deaths occurred in a group of 106 infarct suvivors receiving alprenolol for two years as opposed to 14 deaths out of 108 patients receiving placebo.'8 Further subgroup analyses were performed and showed that there were three sudden deaths in the alprenolol and 11 in the placebo groups, but a general note of caution needs to be sounded, for if 50 subgroups were to be scrutinised retrospectively in a trial, one of them could show spurious significance (type I error) at the p=0-02 level.
In 1975 a much larger late-entry trial of practolol was reported.'9 This time the total deaths in the original intentionto-treat groups were 94 out of 1524 patients treated with practolol and 117 out of 1514 patients treated with placebonot an impressive difference. However, when the deaths in patients still on treatment were compared or when further subgroups not allowed for in the original trial design were analysed the authors argued that patients with anterior infarction who continued on treatment were especially helped. The dangers of such retrospective analysis as opposed to prospective allocation on the basis of predetermined entry criteria must again be emphasised. However, the occurrence of serious, long-term side effects with practolol meant that the continuing debate about how to analyse the results became pointless.
Finally, a Danish group20 reported that treatment with alprenolol, initiated soon after admission, reduced the 12-month death rate in patients under 65 (13 deaths out of 140 treated with alprenolol and 29 out of 142 treated with placebo). Their age stratification was prospective, so strictures on retrospective data-dredging do not apply, but when we look at the outcome in the over-65s we find a mirror-image: 48 out of 98 patients treated with alprenolol died but only 35 out of 100 who received placebo. If one now adopts the pragmatic approach and looks at total deaths according to their original intention-to-treat categories, there were 61 deaths in the 238 who received alprenolol and 64 in the 242 who received placebo. As Lewis Carroll2l said: "He thought he saw an argument that proved he was the Pope; he looked again and saw it was a bar of mottled soap; a fact so dread, he faintly said, extinguishes all hope!" Thus, despite claims that they reduce arrhythmias, cardiac work, and infarct size, we still have no clear evidence that beta-blockers improve long-term survival after infarction despite almost 20 years of clinical trials.
Norwegian timolol trial: the design-A Norwegian multicentre study of timolol maleate22 is now being promoted as the answer to all our previous doubts. Over a decade of confusion should, however, prompt us to analyse this study with obsessional care to see how and why it differs from its predecessors. The 20 centres concerned serve a catchment population of 1-3 million, and for 21 months they registered for consideration for the trial all the men and women aged between 20 and 75 in whom myocardial infarction was suspected on arrival in hospital. If we regard what is to follow as a hurdle race (see figure), we thus have 11 125 individuals who jumped the first obstacle labelled "suspected infarction," and such an accession rate seems to be broadly in keeping with the size of population served. After an unrevealed time interval 4155 patients went on to jump the next hurdle by achieving certain diagnostic criteria for myocardial infarction.
Herein lies the first of a series of questions which we must pose as we scrutinise the report and which must be answered by the organisers. We can guess that infarction had been diagnosed before the sixth day in some patients and by the 27th in everyone, because the next hurdle, which was evaluation for randomisation into the trial, had to lhave been jumped before these days. The au-thors do not actually tell us the timing of diagnosis in their 4155 patients, and without this critical point on the timescale of infarct management we cannot judge many of their subsequent results. For example, 1567 6970 (62.6%) of their 11 125 suspected infarcts failed to jump the diagnostic hurdle, and as some of the criteria used (for example, non-specific electrocardiographic changes plus a minimal increase in enzyme concentrations) would have recruited infarcts which have been classified in other trials as "possibles" and "probables" rather than "definites,"23-25 one is surprised to find that with such a low threshold their suspected:diagnosed ratio was still 2:1. In most coronary care units a ratio of 1 :1 or 1:2 is the norm,26 so the authors must tell us the alternative diagnoses and the death rate in their 6970 non-infarct patients so that we can assess the relevance for example, occurred in 1400 of the placebo entrants, but in only 10'"() of the timolol entrants). In a trial of this size this is a very large difference, as are the differences in "treated hypertension" (22'%o v 18l) and previous diuretic use (23% v 18%). These sizeable differences are significant at the p=0 05-0-01 level, so if the groups differed systematically in ways which could influence prognosis one only requires a further one in 10 spin of the wheel of chance to achieve their total mortality figures. While we may have baulked at accepting a one in 1000 possibility that the 54 differential deaths were due to chance, we can more readily conceive of a one in 10 possibility that a type I error has occurred by the operation of chance on top of an inbuilt disparity in predictors of outcome between two imbalanced groups. The authors suggest that by "adjusting for the largest differences and other factors considered prognostically important" they can overcome the inequality of the two groups, but I do not believe that this can be done.6 The techniques used can only adjust for overt variables, and if, as a group, the placebo patients also have related but hidden adverse factors such as platelet hyperreactivity29 then no amount of adjustment for the overt differences can overcome this hidden initial imbalance.
We can, therefore, judge for ourselves that the groups were not "well balanced on entry" but by a simple oversight we are denied another piece ofevidence about their parity. We are told that the mean interval before randomisation was 11-6 days in the placebo group and 11-4 days in the timolol group, but we are not given any reassurance about the distribution of these entry days. In theory, one group could all have been entered at 11 and 12 days, whereas the other could have had two subgroups clustered at seven days and 28 days, giving very dissimilar risk potentials. A simple standard error or median and modal figures would have readily resolved this point.
Have all the results been presented ?-In the Danish alprenolol study20 benefit occurred in patients under 65, while older patients fared worse on alprenolol than on placebo. The present trial shows that older patients did better in terms of cardiac mortality (64 and under: placebo 54 deaths and timolol 30; 65 and over: placebo 59 deaths and timolol 28). Though the end point is softer, this age effect is even more striking for reinfarction (64 and under: placebo 72 and timolol 55; 65 and over: placebo 69 and timolol 33). Age at infarction is strongly sexrelated, so it is odd that no separate analyses for men and women are provided, since the apparent increasing benefit with age might reflect a greater effect in women than in men.
In comparison with the practolol trial,19 where anterior infarcts appeared to benefit most, the relative benefit of timolol in terms of cardiac death was greater in inferior and "other and uncertain" infarcts than in anteriorly-sited ones. If betablockade is producing these benefits, why do the effects of age and infarct-size differ with alprenolol, practolol, and timolol ?
Finally, though the smoking habits of the groups are reported, the outcome in the treated and placebo groups is not analysed for smoking status. At the Oslo meeting which coincided with the publication ofreports of the trial22 data were presented which hinted that the effect of timolol was less strong in infarct survivors who had given up smoking and was greatest in continuing smokers. Until this information appears in print, together with the answers to all the other questions I have posed, we should not make major prescribing and policy decisions.
What might the results mean ?-If we now forget all these niggling doubts and accept the results at face value, we should ask, "How could timolol reduce the death rate so markedly in infarct survivors when other beta-blockers have given 1569 conflicting results ?" We get no immediate clue from the known properties of the drug itself, which is an unremarkable beta-blocker.22 (It is non-selective, has little intrinsic sympathomimetic activity, and a similar level of membrane stabilising activity to propranolol, oxprenolol, and alprenolol.) If we had been seeking a member of this large group which had unique properties in respect of its known beta-blocking characteristics, we would not have picked timolol. However, when we look at its structural formula, a different possibility begins to emerge. Most current beta-blockers have a structure which resembles that of the catecholamines which they antagonise (an aromatic ring with a substituted ethanolamine side chain linked to it by an OCH2 group). Timolol also has a catecholamine-mimicking side chain, but it is attached to a five-membered heterocyclic ring containing nitrogen and sulphur (a thiadazole), which in its turn is attached to another heterocyclic ring containing nitrogen and oxygen (a morpholino compound). Moreover, timolol is presented as a maleate. Is it possible that the side chain confers completely unremarkable beta-blocking properties on the molecule and that these unremarkable properties allow timolol to share with its other beta-blocking colleagues an inability to modify the natural history of myocardial infarction, whereas the thiadazole-morpholino structure confers on timolol as-yet unsuspected antiarrhythmic, infarct-size-limiting, or plateletmodifying activities ? No doubt the pharmaceutical industry will now be synthesising compounds which possess this ring structure but which lack the beta-blocking side chain so that these possibilities can be explored.
Learning from the past, looking to the future, but living in the present-What, then, do I advise, having taken you on a journey from clinical trials with bullocks in Old Testament Israel to the enhanced survival of myocardial infarction patients in Norway ?
To practising doctors-Even if the timolol and placebo groups had been balanced for overt and hidden adverse prognostic factors on entry the observed difference of 54 deaths out of 11 125 suspected infarcts and 4155 diagnosed infarcts could still have arisen by chance. To put it at its simplest, if 50 trials of beta-blockers had been carried out a spuriously positive result could arise in one of them with a p value of 0-02. It will be argued that far fewer than 50 major beta-blocker trials have in fact been reported, but we must remember the reluctance of editors to accept, and of authors to offer, negative trial results; in any condition reports of positive associations always outnumber valid but unexciting negative reports. Practising doctors must, therefore, ask themselves whether they wish to deny potential benefit to their patients while we continue to dissect the timolol trial ? If they do not, they can use a drug which has few side effects (other than those which it shares with other beta-blockers) to try to give their patients the benefit which the 54 differential survivors received. There is still a one in a 1000 chance that tomorrow's clinical trials of timolol will produce different results, but should we not try to help today's patients if we know that we can do so safely ? For most clinicians, the answer must be "yes."3
To my Norwegian colleagues-You must now provide additional information on the following points: the diagnoses and fate of the 6970 "non-infarct" patients; the precise timing of infarct diagnosis; the death rate in the 1763 excluded infarcts; the reasons for the sizeable and unilateral differences in risk attributes at entry between the groups; the details of the outcome in men and women; and, finally, the survival patterns in treated and untreated smokers and non-smokers.
To other trialists-Because the timolol trial did not begin until the 11th day on average, and the 28th day for some patients, you have what the National Aeronautics and Space Administration would call a "window" from admission with suspected infarction to this entry point in which you can justifiably scrutinise any regimen against placebo. You may feel that timolol itself should be assessed against placebo in an acute-entry trial, beginning with intravenous loading doses to ensure rapid maximal beta-blockade.30 In any event no ethical considerations arise for trialists planning 0-28 day studies of other beta-blockers, antiarrhythmics, or antithrombotics. It is from 28 days to 17 months that the going gets tough, but on balance, I would advise that the problem of infarct survival is of such magnitude and that the implications of the premature acceptance of a single positive trial are so enormous that you must continue to do further placebocontrolled trials. I accept the taxing ethical implications, but I believe that the end justifies the means, and I consider that we should not prejudice our chances of reassessing the true contribution made by timolol, or of assessing the value of anticoagulants, sulphinpyrazone, thromboxane synthetase inhibitors, stable prostacyclin analogues, and thromboxane receptor blockers by insisting that all of them should either be tested against timolol or tested in combination with timolol against timolol alone. To do so might prevent us offering to millions of patients in years to come a much greater improvement in survival than may eventually be revealed for timolol.
To the pharmaceutical industry-Many of today's drugs started life wearing other hats until chance showed that they had unexpected and valuable additional properties. Indeed, timolol itself seems to be particularly useful in glaucoma, so I would urge you to look at the other ways in which your drug might possess unique effects. I would begin by asking whether its heterocyclic ring structure confers on it added infarctmodifying properties unrelated to its conventional betablocking effects ? For example, does it affect calcium fluxes across cell and mitochondrial membranes31 so that it protects the heart against the calcium overload produced by ischaemia or does it reduce platelet reactivity ? Valediction-It has been said, "Examinations hold terror even for the best prepared, for the greatest fool can ask what the wisest man cannot answer." So, too, with clinical trials, which are desperately hard to do but all too easy to criticise. Years of hard slog may serve merely to expose the trialists to a barrage of criticism and questions. If, however, we are to arrive at a conclusion with the same confidence as Elijah's audience, where "all the people answered and said, it is well spoken," we have no choice but to subject each major trial in common life-threatening diseases to the morbid scrutiny which I have indulged in here. To the Norwegian trialists I would, therefore, say, "Mea culpa; undskyld meg; like you, I am only seeking the truth." J R A MITCHELL Professor of Medicine,
